The Food and Drug Administration approved Geron Corp.'s (Nasdaq: GERN) study to treat spinal cord injuries with human embryonic stem cells, the first study of its kind in the world. Shares of the biopharmaceutical leaped $2.49 to $7.70.
Geron's Stem Cell Study Approved
January 23, 2009 at 12:58 PM EST
